Dr. McGill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2275 Half Day Rd.
Suite 200
Bannockburn, IL 60015
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Child Neurology, 2010 - 2013- Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 2008 - 2010
Baylor College of MedicineClass of 2008, MD
Baylor College of MedicinePh.D., Neuroscience, 2007- Denison UniversityBS, Biology, Magna Cum Laude, 1999
Certifications & Licensure
IL State Medical License 2019 - 2026
OH State Medical License 2019 - 2026
MO State Medical License 2011 - 2025- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Heart AssociationBLS
- American Heart AssociationPALS
Awards, Honors, & Recognition
- Arthur L. Prensky Award for Outstanding Teaching by a Pediatric Neurology Attending Washington University in St. Louis, 2018
- Neurology Clerkship Student Teaching Award Washington University in St. Louis, 2016
- Arthur L. Prensky Award for Outstanding Teaching by a Pediatric Neurology Attendin Washington University in St. Louis, 2015
- Join now to see all
Clinical Trials
- AFQ056 for Language Learning in Children With FXS Start of enrollment: 2017 Aug 17
- Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 Start of enrollment: 2018 Apr 02
Publications & Presentations
PubMed
- 112 citationsCrh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndromeRodney C. Samaco, Caleigh Mandel-Brehm, Christopher M. McGraw, Chad A. Shaw, Bryan E. McGill
Nature Genetics. 2012-02-01 - 130 citationsOnasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell
Nature Medicine. 2022-07-01 - 114 citationsOnasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell
Nature Medicine. 2022-07-01
Grant Support
- Anxiety In A Mouse Model Of Rett SyndromeNational Institute Of Mental Health2003–2006
Professional Memberships
- Member
- Society for NeuroscienceMember
- Child Neurology SocietyMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
